Supreme Court Adopts Reasonable Certainty Test for Definiteness

10 June 2014 PharmaPatents Blog

On June 2, 2014, the Supreme Court issued a unanimous decision in Nautilus, Inc. v. Biosig Instruments, Inc., rejecting the Federal Circuit’s “insolubly ambiguous” test for patent claim indefiniteness under 35 USC § 112, and instead adopting a “reasonable certainty test.” The Court vacated the Federal Circuit decision rendered under the “insolubly ambiguous” test, and remanded for the Federal Circuit to evaluate Biosig’s claims under the new standard.

The Patent at Issue

The patent at issue was Biosig’s U.S. Patent 5,337,753, directed to a heart rate monitor associated with an exercise apparatus and/or exercise procedures. At issue was claim language regarding a “spaced relationship” between electrodes positioned on an “elongate member” that  is held by the user to obtain a heart rate measurement. (Please see this article for a more detailed discussion of this case.)

The Prior Proceedings

The district court construed the term “spaced relationship” to mean that “there is a defined relationship between the live electrode and the common electrode on one side of the cylindrical bar and the same or a different defined relationship between the live electrode and the common electrode on the other side of the cylindrical bar,” and held the term indefinite because it “did not tell me or anyone what precisely the space should be . . . . Not even any parameters as to what the space should be . . . . Nor whether the spaced relationship on the left side should be the same as the spaced relationship on the right side.”

The Federal Circuit reversed, applying an “insolubly ambiguous” test that would hold a claim indefinite only if it is “not amenable to construction.” With reference to the claim language at issue, the court stated:

When a “word of degree” is used, the court must determine whether the patent provides “some standard for measuring that degree.” …. Similarly, when a claim limitation is defined in “purely functional terms,” a determination of whether the limitation is sufficiently definite is “highly dependent on context (e.g., the disclosure in the specification and the knowledge of a person of ordinary skill in the relevant art . . . ).”

The court determined that the “claim language, specification, and … figures” of the ‘753 patent “provide sufficient clarity to skilled artisans as to the bounds of this disputed term.”

The Supreme Court Decision

The Supreme Court decision recognizes that the standard for indefiniteness must balance two competing interests: permitting “[s]ome modicum of uncertainty” to provide “appropriate incentives for innovation” while requiring enough precision “to afford clear notice of what is claimed” and disincentivize the deliberate creation of “zone[s] of uncertainty” around claim scope. The Court determined that these interests are best balanced when the statute is read “to require that a patent’s claims, viewed in light of the specification and prosecution history, inform those skilled in the art about the scope of the invention with reasonable certainty.”

Although the Court took some time to explain the questions presented by the claims at issue, it refused to apply the new “reasonable certainty” test in the first instance, instead remanding to the Federal Circuit. Thus, it will be up to the Federal Circuit in the first instance to determine how to assess whether Biosig’s claims define its invention with “reasonable certainty”.

Unreasonable Uncertainty

Although the Supreme Court calls for “reasonable certainty” in claim language, its decision leaves a “zone of uncertainty” around what is required to satisfy § 112. By pronouncing a new test without applying it to the claims at issue, the Court does little more than discredit the Federal Circuit’s approach without providing even a “modicum” of guidance on the correct standard.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ